Technical Analysis for BCYC - Bicycle Therapeutics plc
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| D | 20.29 | 0.25% | 0.05 |
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 200 DMA Support | Bullish | 0.00% | |
| Multiple of Ten Bullish | Other | 0.00% | |
| Outside Day | Range Expansion | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| 200 DMA Support | Bullish | 0.25% | |
| Stochastic Buy Signal | Bullish | 0.25% | |
| NR7 | Range Contraction | 0.25% | |
| Narrow Range Bar | Range Contraction | 0.25% | |
| Inside Day | Range Contraction | 0.25% | |
| Oversold Stochastic | Weakness | 0.25% |
| Alert | Time |
|---|---|
| Rose Above Previous Day's High | about 5 hours ago |
| Outside Day | about 5 hours ago |
| Up 1% | about 5 hours ago |
| 60 Minute Opening Range Breakout | about 5 hours ago |
| 200 DMA Support | about 9 hours ago |
Get this analysis on your stocks daily!
- Earnings date: 08/01/2024
Bicycle Therapeutics plc Description
Bicycle Therapeutics Limited, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also comprise BT5528, a BTC that is in preclinical studies targeting EphA2; BT8009, which is in preclinical studies targeting Nectin-4; and CD137, an immune cell co-stimulatory molecule that is in preclinical stage, as well as systemically-delivered activators. In addition, it is developing THR-149, a key immune cell co-stimulatory molecule that is in Phase I clinical trials. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas, such as anti-infective, cardiovascular, hematology, ophthalmology, and respiratory indications. The company has a clinical trial and license agreement with the Cancer Research Technology Limited and CRUK; and research collaboration agreement with Bioverativ Inc., AstraZeneca AB, and Oxurion NV. The company was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Life Sciences Disease Immunology Oncology Tumor Ophthalmology Hematology Immune Checkpoint Cancer Research Search Technology
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 27.5 |
| 52 Week Low | 12.54 |
| Average Volume | 321,748 |
| 200-Day Moving Average | 20.15 |
| 50-Day Moving Average | 22.46 |
| 20-Day Moving Average | 21.96 |
| 10-Day Moving Average | 20.52 |
| Average True Range | 0.99 |
| RSI (14) | 37.11 |
| ADX | 18.61 |
| +DI | 19.01 |
| -DI | 25.94 |
| Chandelier Exit (Long, 3 ATRs) | 22.00 |
| Chandelier Exit (Short, 3 ATRs) | 22.78 |
| Upper Bollinger Bands | 25.06 |
| Lower Bollinger Band | 18.87 |
| Percent B (%b) | 0.23 |
| BandWidth | 28.18 |
| MACD Line | -0.73 |
| MACD Signal Line | -0.52 |
| MACD Histogram | -0.2111 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 21.33 | ||||
| Resistance 3 (R3) | 21.28 | 20.89 | 21.15 | ||
| Resistance 2 (R2) | 20.89 | 20.63 | 20.91 | 21.09 | |
| Resistance 1 (R1) | 20.59 | 20.46 | 20.74 | 20.64 | 21.04 |
| Pivot Point | 20.20 | 20.20 | 20.28 | 20.22 | 20.20 |
| Support 1 (S1) | 19.90 | 19.94 | 20.05 | 19.95 | 19.54 |
| Support 2 (S2) | 19.51 | 19.77 | 19.53 | 19.49 | |
| Support 3 (S3) | 19.21 | 19.51 | 19.43 | ||
| Support 4 (S4) | 19.26 |
